Clinical trial
Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder: A Pilot Study
NCT06477263 is registered in ClinicalTrials.gov with Neurocytonix, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder: A Pilot Study
- Lead sponsor
- Neurocytonix, Inc.
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- July 15, 2024
- Completion date
- September 30, 2025
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.